Evidence map›Paper›PMID 34777687›Full record

ReviewOxidative medicine and cellular longevity2021

Quercetin Impact in Pancreatic Cancer: An Overview on Its Therapeutic Effects.

Parina Asgharian, Abbas Pirpour Tazehkand, Saiedeh Razi Soofiyani, Kamran Hosseini, Miquel Martorell, Vahideh Tarhriz, Hossein Ahangari, Natália Cruz-Martins, Javad Sharifi-Rad, Zainab M Almarhoon and 4 more

Open access · hybridAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Oxidative medicine and cellular longevity, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 2 pooled it
3.4field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 2 syntheses or guidelines pooled it, 54 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Review
  13. Article
  14. Review
  15. Review
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 8 institutions in 7 countries.

Parina AsgharianDrug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Abbas Pirpour TazehkandDepartment of Biochemistry and Clinical Laboratories, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran.
Saiedeh Razi SoofiyaniClinical Research Development Unit of Sina Educational, Research and Treatment Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Kamran HosseiniStudent Research Committee, Shiraz University of Medical Sciences, Shiraz, Iran.
Miquel MartorellDepartment of Nutrition and Dietetics, Faculty of Pharmacy and Centre for Healthy Living, University of Concepción, 4070386 Concepción, Chile.ORCID https://orcid.org/0000-0003-3183-7623
Vahideh TarhrizMolecular Medicine Research Center, Biomedicine Institute, Tabriz University of Medical Sciences, Tabriz, Iran.ORCID https://orcid.org/0000-0002-3018-9313
Hossein AhangariDepartment of Food Science and Technology, Faculty of Nutrition and Food Science, Tabriz University of Medical Sciences, Tabriz, Iran.ORCID https://orcid.org/0000-0002-1450-1063
Natália Cruz-MartinsDepartment of Biomedicine, Faculty of Medicine, University of Porto, Alameda Prof. Hernâni Monteiro, Porto, Portugal.ORCID https://orcid.org/0000-0002-5934-5201
Javad Sharifi-RadFacultad de Medicina, Universidad del Azuay, Cuenca, Ecuador.ORCID https://orcid.org/0000-0002-7301-8151
Zainab M AlmarhoonDepartment of Chemistry, College of Science, King Saud University, P. O. Box 2455, Riyadh 11451, Saudi Arabia.ORCID https://orcid.org/0000-0001-8196-2612
Alibek YdyrysBiomedical Research Centre, Al-Farabi Kazakh National University, Al-Farabi Av. 71, 050040 Almaty, Kazakhstan.
Ablaikhanova NurzhanyatDepartment of Biophysics, Biomedicine and Neuroscience, Al-Farabi Kazakh National University, Al-Farabi Av. 71, 050040 Almaty, Kazakhstan.
Arailym YessenbekovaDepartment of Biophysics, Biomedicine and Neuroscience, Al-Farabi Kazakh National University, Al-Farabi Av. 71, 050040 Almaty, Kazakhstan.
William C ChoDepartment of Clinical Oncology, Queen Elizabeth Hospital, Kowloon, Hong Kong, China.ORCID https://orcid.org/0000-0003-4174-4586
Tabriz University of Medical Sciences · IRAl-Farabi Kazakh National University · KZKing Saud University · SAQueen Elizabeth Hospital · CNShiraz University of Medical Sciences · IRUniversidad del Azuay · ECUniversidade do Porto · PTUniversity of Concepción · CL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pancreatic cancer (PC) is a lethal malignancy cancer, and its mortality rates have been increasing worldwide. Diagnosis of this cancer is complicated, as it does not often present symptoms, and most patients present an irremediable tumor having a 5-year survival rate after diagnosis. Regarding treatment, many concerns have also been raised, as most tumors are found at advanced stages. At present, anticancer compounds-rich foods have been utilized to control PC. Among such bioactive molecules, flavonoid compounds have shown excellent anticancer abilities, such as quercetin, which has been used as an adjunctive or alternative drug to PC treatment by inhibitory or stimulatory biological mechanisms including autophagy, apoptosis, cell growth reduction or inhibition, EMT, oxidative stress, and enhancing sensitivity to chemotherapy agents. The recognition that this natural product has beneficial effects on cancer treatment has boosted the researchers' interest towards more extensive studies to use herbal medicine for anticancer purposes. In addition, due to the expensive cost and high rate of side effects of anticancer drugs, attempts have been made to use quercetin but also other flavonoids for preventing and treating PC. Based on related studies, it has been found that the quercetin compound has significant effect on cancerous cell lines as well as animal models. Therefore, it can be used as a supplementary drug to treat a variety of cancers, particularly pancreatic cancer. This review is aimed at discussing the therapeutic effects of quercetin by targeting the molecular signaling pathway and identifying antigrowth, cell proliferation, antioxidative stress, EMT, induction of apoptotic, and autophagic features.

Indexed as

Oxidative StressAnimalsAntineoplastic Agents, PhytogenicCell ProliferationHumansPancreatic NeoplasmsQuercetinAntineoplastic Agents, PhytogenicQuercetin

Identifiers

PMID34777687
PMCPMC8580629
OpenAlexW3208561810

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.